A new two-dose coronavirus vaccine by European drugmakers Sanofi and GSK shows a 100% effectiveness rate in preventing severe Covid cases and hospitalizations, the New York Times reports.
Sanofi and GSK and received billions of dollars from the Trump Administration’s Operation Warp Speed in 2020, and it becomes the last of four major drugmakers which receive those funds to introduce a vaccine. Sanofi recorded $14 billion in net income in 2020; GSK logged $7.3 in annual income in 2020.
The vaccine, which has yet to receive FDA approval, could also be used a third booster shot. In a Phase 3 clinical trial, the Sanofi/GSK formula shows 58% efficacy against symptomatic disease and a 75% efficacy against moderate to severe disease.
The vaccine is not an mRNA vaccine like Pfizer and Moderna, which are approved in the US. It’s formulation, the companies claim, stimulates the body to produce more antibodies than their mRNA counterparts.